Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Therapeutic drug and diagnostic company Fusion Antibodies reported narrower losses in the first half of the year compared with a year earlier as higher revenue offset increased costs.
For the six months ended 30 September 2020, pre-tax losses narrowed to £572,000 from £616,000 year-on-year as revenue increased to £1.90 million from £1.75 million, in line with management's expectations.
R&D expenditure rose 50% to £271,000.
Looking ahead, the company outlined two major uncertainties including Brexit and the impact of Covid-19 restrictions on its supply chain.
At 8:38am: (LON:FAB) Fusion Antibodies Plc Ord 4p share price was 0p at 132.5p